Generic insulin price cap brings relief to nine million

Pharma lobby warns of supply strain; patients’ groups call the move long overdue.

In New Delhi, the change was felt first by the people who track it for a living. What happens next depends less on the headline than on the follow-through.

The story, as ever, is in the distribution: who gains, who waits, and how long the advantage lasts once the initial momentum fades. That is the question this week leaves open.